Literature DB >> 27471234

T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire.

Ruth A Ettinger1, Pedro Paz2, Eddie A James3, Devi Gunasekera1,4, Fred Aswad2, Arthur R Thompson1,5, Dana C Matthews6,7, Kathleen P Pratt1,4,5.   

Abstract

Factor VIII (FVIII)-neutralizing antibodies ("inhibitors") are a serious problem in hemophilia A (HA). The aim of this study was to characterize HLA-restricted T-cell responses from a severe HA subject with a persistent inhibitor and from 2 previously studied mild HA inhibitor subjects. Major histocompatibility complex II tetramers corresponding to both of the severe HA subject's HLA-DRA-DRB1 alleles were loaded with peptides spanning FVIII-A2, C1, and C2 domains. Interestingly, only 1 epitope was identified, in peptide FVIII2194-2213, and it was identical to the HLA-DRA*01-DRB1*01:01-restricted epitope recognized by the mild HA subjects. Multiple T-cell clones and polyclonal lines having different avidities for the peptide-loaded tetramer were isolated from all subjects. Only high- and medium-avidity T cells proliferated and secreted cytokines when stimulated with FVIII2194-2213 T-cell receptor β (TCRB) gene sequencing of 15 T-cell clones from the severe HA subject revealed that all high-avidity clones expressed the same TCRB gene. High-throughput immunosequencing of high-, medium-, and low-avidity cells sorted from a severe HA polyclonal line revealed that 94% of the high-avidity cells expressed the same TCRB gene as the high-avidity clones. TCRB sequencing of clones and lines from the mild HA subjects also identified a limited TCRB gene repertoire. These results suggest a limited number of epitopes in FVIII drive inhibitor responses and that the T-cell repertoires of FVIII-responsive T cells can be quite narrow. The limited diversity of both epitopes and TCRB gene usage suggests that targeting of specific epitopes and/or T-cell clones may be a promising approach to achieve tolerance to FVIII.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27471234      PMCID: PMC5073183          DOI: 10.1182/blood-2015-11-682468

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  73 in total

1.  Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity.

Authors:  S Webb; C Morris; J Sprent
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

Review 2.  Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.

Authors:  Giancarlo Castaman; Karin Fijnvandraat
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

3.  Alterations of T cell receptor Vbeta repertoire of CD8 T lymphocytes in immune tolerance induction in two hemophilia A patients with inhibitors.

Authors:  Yoshihiko Sakurai; Takaji Matsutanit; Takeshi Yoshioka; Tomohiro Takeda; Akira Yoshioka; Midori Shima
Journal:  Vojnosanit Pregl       Date:  2011-12       Impact factor: 0.168

4.  Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule.

Authors:  Yili Li; Yuping Huang; Jessica Lue; Jacqueline A Quandt; Roland Martin; Roy A Mariuzza
Journal:  EMBO J       Date:  2005-08-04       Impact factor: 11.598

Review 5.  The incidence of inhibitor development according to specific mutations--and treatment?

Authors:  Anne Goodeve
Journal:  Blood Coagul Fibrinolysis       Date:  2003-06       Impact factor: 1.276

6.  T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide.

Authors:  E A James; W W Kwok; R A Ettinger; A R Thompson; K P Pratt
Journal:  J Thromb Haemost       Date:  2007-12       Impact factor: 5.824

Review 7.  Progress toward inducing immunologic tolerance to factor VIII.

Authors:  David W Scott; Kathleen P Pratt; Carol H Miao
Journal:  Blood       Date:  2013-03-15       Impact factor: 22.113

8.  Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses.

Authors:  Ruth A Ettinger; Eddie A James; William W Kwok; Arthur R Thompson; Kathleen P Pratt
Journal:  Blood       Date:  2009-06-23       Impact factor: 22.113

9.  IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes.

Authors:  Véronique Giudicelli; Denys Chaume; Marie-Paule Lefranc
Journal:  Nucleic Acids Res       Date:  2005-01-01       Impact factor: 16.971

10.  Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.

Authors:  Jasper C Lin; Ruth A Ettinger; Jason T Schuman; Ai-Hong Zhang; Muhammad Wamiq-Adhami; Phuong-Cac T Nguyen; Shelley M Nakaya-Fletcher; Komal Puranik; Arthur R Thompson; Kathleen P Pratt
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

View more
  9 in total

1.  FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.

Authors:  Ruth A Ettinger; Joseph A Liberman; Devi Gunasekera; Komal Puranik; Eddie A James; Arthur R Thompson; Kathleen P Pratt
Journal:  Blood Adv       Date:  2018-02-27

Review 2.  Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia

Authors:  Richard S Blumberg; David Lillicrap
Journal:  Blood       Date:  2018-03-27       Impact factor: 22.113

3.  Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.

Authors:  Patricia E Zerra; Courtney Cox; W Hunter Baldwin; Seema R Patel; Connie M Arthur; Pete Lollar; Shannon L Meeks; Sean R Stowell
Journal:  Blood       Date:  2017-10-04       Impact factor: 22.113

Review 4.  Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A.

Authors:  Alexandra Sherman; Moanaro Biswas; Roland W Herzog
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

5.  Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition.

Authors:  Dina Schneidman-Duhovny; Natalia Khuri; Guang Qiang Dong; Michael B Winter; Eric Shifrut; Nir Friedman; Charles S Craik; Kathleen P Pratt; Pedro Paz; Fred Aswad; Andrej Sali
Journal:  PLoS One       Date:  2018-11-06       Impact factor: 3.240

Review 6.  Modulation of immune responses in lentiviral vector-mediated gene transfer.

Authors:  Andrea Annoni; Silvia Gregori; Luigi Naldini; Alessio Cantore
Journal:  Cell Immunol       Date:  2018-04-27       Impact factor: 4.868

Review 7.  Tolerating Factor VIII: Recent Progress.

Authors:  Sebastien Lacroix-Desmazes; Jan Voorberg; David Lillicrap; David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

Review 8.  Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.

Authors:  David W Scott; Kathleen P Pratt
Journal:  Front Immunol       Date:  2020-01-17       Impact factor: 8.786

Review 9.  Specificity of the T Cell Response to Protein Biopharmaceuticals.

Authors:  Sylvain Meunier; Marie de Bourayne; Moustafa Hamze; Aurélien Azam; Evelyne Correia; Catherine Menier; Bernard Maillère
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.